Västerås, Sweden, June 16, 2026 - Scandinavian Real Heart AB (publ) today released the recording of the Annual General Meeting held at the Company’s new premises in Västerås on May 28, 2026.

Västerås, Sweden, June 16, 2026 - Scandinavian Real Heart AB (publ) today released the recording of the Annual General Meeting held at the Company’s new premises in Västerås on May 28, 2026.

In connection with the Company’s Annual General Meeting, CEO Ina Laura Perkins gave an updated presentation on the current status of the Company’s total artificial heart, Realheart® TAH, to the shareholders in attendance. This time, the entire management team, and the Board of Directors were also present.

The recording, which is just over 27 minutes long, is primarily in Swedish, but also includes segments in English where the management and board members introduce themselves.

Link to the recording: https://youtu.be/sQDKo1fs824

For more information, please contact:Ina Laura Perkins, CEOPhone: +46 (0) 70 406 49 21 E-mail: inalaura.perkins@realheart.seCertified Adviser: Svensk Kapitalmarknadsgranskning AB, www.skmg.se

About UsScandinavian Real Heart AB (publ) is developing the first artificial heart that mimics the shape, function, and blood flow pattern of the human heart. These unique product features provide completely new opportunities to save lives and give patients a good quality of life while waiting for a heart transplant. In the future, artificial hearts may also become an alternative to transplantation for broader groups of patients with severe heart failure. Realheart® TAH (Total Artificial Heart) is now being evaluated in extensive preclinical trials ahead of a first clinical study in patients. The company's shares are traded on Nasdaq Stockholm First North Growth Market. For more information, visit www.realheart.se

For more information, please contact:Ina Laura Perkins, CEOPhone: +46 (0) 70 406 49 21 E-mail: inalaura.perkins@realheart.seCertified Adviser: Svensk Kapitalmarknadsgranskning AB, www.skmg.se

About UsScandinavian Real Heart AB (publ) is developing the first artificial heart that mimics the shape, function, and blood flow pattern of the human heart. These unique product features provide completely new opportunities to save lives and give patients a good quality of life while waiting for a heart transplant. In the future, artificial hearts may also become an alternative to transplantation for broader groups of patients with severe heart failure. Realheart® TAH (Total Artificial Heart) is now being evaluated in extensive preclinical trials ahead of a first clinical study in patients. The company's shares are traded on Nasdaq Stockholm First North Growth Market. For more information, visit www.realheart.se

AttachmentsRealheart Releases Recording of the 2026 Annual General Meeting